NexgenRxNEGXF 51 EV-to-FCF is 6.57 as of Jul. 03, 2026, which is 53% below its 10-year median of 13.93. GuruFocus rates NEGXF with a GF Score™ of 51/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 406 Healthcare Providers & Services companies, NexgenRx ranks better than 82.02% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NexgenRx's Enterprise Value is $20.88 Mil.
NexgenRx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $3.18 Mil. Therefore, NexgenRx's EV-to-FCF for today is 6.57.
The historical rank and industry rank for NexgenRx's EV-to-FCF or its related term are showing as below:
NEGXF'
s EV-to-FCF Range Over the Past 10 Years
Min: -726.88 Med: 13.93 Max: 838.07
Current: 6.69
During the past 13 years, the highest EV-to-FCF of NexgenRx was 838.07. The lowest was -726.88. And the median was 13.93.
NEGXF's EV-to-FCF is ranked better than 82.02% of 406
companies
in the Healthcare Providers & Services industry
Industry Median: 17.73
vs NEGXF: 6.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NexgenRx's share price for today is $0.325.
NexgenRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NexgenRx EV-to-FCF Related Terms
NexgenRx EV-to-FCF Historical Data
* Premium members only.
The historical data trend for NexgenRx's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, NexgenRx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NexgenRx's EV-to-FCF falls into.
NexgenRx's current Enterprise Value is $20.88 Mil.
NexgenRx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (NEGXF) has a EV-to-FCF of 6.57 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NexgenRx and its competitors. This is 53% below median its historical median of 13.93. According to the industry distribution chart, NexgenRx ranks #73 out of 406 companies in the Healthcare Providers & Services industry, placing it in the top 18%.
Is NexgenRx's EV-to-FCF too high?
NexgenRx's current EV-to-FCF of 6.57 is 53% below median its 10-year median of 13.93. The Healthcare Providers & Services industry median EV-to-FCF is 17.73. NexgenRx's value of 6.57 is 62.9% below this industry median. Based on the distribution chart, NexgenRx ranks #73 out of 406 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NexgenRx has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's EV-to-FCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #73 out of 406 companies for EV-to-FCF. This places NexgenRx in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 17.73. NexgenRx's value of 6.57 is 62.9% below this benchmark. While the company's 10-year median is 13.93 vs. the industry median of 17.73, NexgenRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.73, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current EV-to-FCF of 6.57 is 62.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current EV-to-FCF is 6.57, which is 53% below median its own 10-year median of 13.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current EV-to-FCF is 6.57, which is 53% below median its 10-year median of 13.93 and 62.9% below the Healthcare Providers & Services industry median of 17.73. NexgenRx's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For NexgenRx (NEGXF), the current EV-to-FCF is 6.57 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
EV-to-FCF: 6.57 (53% below median its 10-year median of 13.93)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 62.9% below the Healthcare Providers & Services median (#73 of 406)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
51GF Score
Get the complete analysis for NEGXF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
